Related Experiment Video
Updated: Jul 14, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
Published on: August 8, 2022
[Inherited metabolic cardiomyopathies]
Dominique P Germain1, Ales Linhart, Michel Desnos
1Centre de référence de la maladie de Fabry et des maladies héréditaires du tissu conjonctif (syndromes d'Ehlers-Danlos et pseudoxanthome elastique), Assistance Publique-Hôpitaux de Paris, Paris (75), France. dominique.germain@egp.aphp.fr
Insights
Genetic storage diseases like PRKAG2 deficiency, Danon disease, and Pompe disease cause hypertrophic cardiomyopathy when sarcomeric gene mutations are undetected. These conditions share a short PR interval and require specific management strategies.
Area of Science:
- Cardiology
- Genetics
- Metabolic Diseases
Background:
- Hypertrophic cardiomyopathy (HCM) affects 1/500 individuals.
- Genetic mutations in sarcomeric proteins explain only two-thirds of HCM cases.
- A subset of unexplained HCM is linked to genetic storage diseases.
Purpose of the Study:
- To investigate genetic storage diseases as a cause of HCM.
- To highlight common clinical features and genetic underpinnings of these conditions.
Main Methods:
- Review of genetic analyses for HCM.
- Identification of storage diseases (PRKAG2 deficiency, Danon disease, Pompe disease, Fabry disease) associated with cardiomyopathy.
- Analysis of clinical presentations and genetic mutations.
Main Results:
- PRKAG2 deficiency, an autosomal dominant disorder, causes storage cardiomyopathy with risks of sudden death.
- Danon disease, an X-linked dominant disorder, presents with cardiomyopathy, myopathy, and intellectual disability.
- Pompe disease, particularly infantile form, shows cardiac improvement with enzyme replacement therapy.
Conclusions:
- Genetic storage diseases are crucial differential diagnoses for HCM.
- Common features include short PR interval, necessitating targeted genetic testing.
- Specific therapies are available for some of these conditions, impacting patient outcomes.
Abstract:
Hypertrophic cardiomyopathies have an estimated prevalence of 1/500. The analysis of the genes coding for the 10 most commonly involved sarcomeric proteins, fails to detect a mutation in about one third of cases. In some of these cases, cardiomyopathy can be attributed to a genetics storage disease with enlarged glycogen vacuolss (PRKAG2 deficiency, Danon disease, Pompe disease) and/or lysosomol vacuoles (Donon disease, Pompe disease, Fabry disease). These diseases all have in common a short PR interval. PRKAG2 deficiency is due to a dominant mutation of the gamma2 subunit of the cardiac AMP kinose. It leads to a storage cardiomyopathy which may be associated with sudden death in 10% of cases, due to ventricular arrhythmia or auriculoventricular blocks. Danon disease is an X-linked dominant inherited disease characterized by cardiomyopathy, squeletal myopathy and mental retardation. Cardiac transplantation is indicated in both affected men and women. In the infantile form of Pompe disease, enzyme replacement therapy with olglucosidase alpha shows efficacy on cardiac failure with a significant regression of ventricular hypertrophy on ECG, echocardiography and radiography
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VI: Nursing Management

